Consensus
The community sees this as very unlikely for AstraZeneca at 21%, based on 4 forecasts. Forecasters are in moderate agreement.
Resolves YES if AstraZeneca is down more than 22% 180 days out versus its baseline price.
Share your read on this question — the best forecasters show their work.
See the whole azn discussion →